Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

NCT03008616 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
59
Enrollment
INDUSTRY
Sponsor class

Stopped Following a recommendation from the Data and Safety Monitoring Board (DSMB), the study was stopped early for futility. There were no safety concerns raised.

Conditions

Interventions

Sponsor

AMAG Pharmaceuticals, Inc.